595 Burrard St, Suite 1703
Vancouver, BC V7X 1J1
Phone: (604) 488-5421
Member Sector: Biopharmaceuticals
NervGen is restoring life’s potential by creating innovative solutions for the treatment of nerve damage.
NervGen is advancing its lead compound, NVG-291, for the treatment of spinal cord injury and multiple sclerosis, two indications that have significant market opportunities, are a high cost burden to the healthcare system and have a dramatic impact on quality of life. As a therapy, NVG-291 has shown remarkable preclinical promise to alleviate or improve the symptoms and conditions associated with spinal cord injury and multiple sclerosis, potentially allowing human patients to live more active and productive lives. There are currently no therapeutics approved for either nerve regeneration or remyelination.
In addition to spinal cord injury and multiple sclerosis, the Company is embarking on a research initiative to advance its proprietary therapeutic technology platform to generate new treatments for Alzheimer’s disease, a progressive neurodegenerative disorder that destroys memory and cognitive functions.